Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:43 AM
Ignite Modification Date:
2025-12-25 @ 2:43 AM
NCT ID:
NCT01002833
Eligibility Criteria:
Inclusion Criteria:
* Age \> 18 and \< 35 years healthy volunteers (males or females)
* General good health based on history and clinical examination
* Negative pregnancy test
* Use of adequate contraception for females
* All volunteers have to sign the informed consent form following proper understanding of the meaning and procedures of the study
* Volunteer agrees to inform the general practitioner and agrees to sign a request for medical information concerning contra-indications for participation in the study
* Willingness to undergo a Pf sporozoite challenge
* Agreement to stay in a hotel room close to the trial center during a part of the study (Day 5 till Day T +3)
* Reachable by mobile phone during the whole study period
* Available to attend all study visits
* Agreement to refrain from blood donation to Sanquin or for other purposes, during the course of the study
* Willingness to undergo an HIV, hepatitis B and C test
* Negative urine toxicology screening test at screening visit and day before challenge
* Willingness to take a curative regimen of Malarone®
Exclusion Criteria:
* History of malaria
* Plans to travel to endemic malaria areas during the study period
* Previous participation in any malaria vaccine study and/or positive serology for Pf
* Symptoms, physical signs and laboratory values suggestive of systemic disorders, including renal, hepatic, cardiovascular, pulmonary, skin, immunodeficiency, psychiatric and other conditions, which could interfere with the interpretation of the study results or compromise the health of the volunteers
* History of diabetes mellitus or cancer (except basal cell carcinoma of the skin)
* History of arrhythmia's or prolonged QT-interval
* Positive family history in 1st and 2nd degree relatives for cardiac disease \< 50 years old
* An estimated, ten year risk of fatal cardiovascular disease of ≥5%, as estimated by the Systematic Coronary Risk Evaluation (SCORE) system
* Body Mass Index (BMI) below 18 or above 30 kg/m2
* Any clinically significant deviation from the normal range in biochemistry or haematology blood tests or in urine analysis
* Positive HIV, HBV or HCV tests
* Participation in any other clinical study within 30 days prior to the onset of the study
* Volunteers enrolled in any other clinical study during the study period
* Pregnant or lactating women
* Volunteers unable to give written informed consent
* Volunteers unable to be closely followed for social, geographic or psychological reasons
* Previous history of drug or alcohol abuse interfering with normal social function during a period of one year prior to enrolment in the study
* A history of psychiatric disease
* Known hypersensitivity for anti-malaria drugs
* History of severe reactions or allergy to mosquito bites
* The use of chronic immunosuppressive drugs, antibiotics, or other immune modifying drugs within three months before study onset (inhaled and topical corticosteroids are allowed) and during the study period
* Contra-indications to Malarone® including treatment taken by the volunteers that interfere with Malarone®
* Any confirmed or suspected immunosuppressive or immunodeficiency condition, including asplenia
* Co-workers of the departments of Medical Microbiology or Internal Medicine of the Radboud University Nijmegen Medical Centre or Leiden University Medical Center
* A history of sickle cell, thalassaemia trait and G6PD deficiency
Healthy Volunteers:
True
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
35 Years
Study:
NCT01002833
Study Brief:
Protocol Section:
NCT01002833